論文

査読有り
2004年5月

Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
  • Y Ozaki
  • ,
  • K Kontani
  • ,
  • K Teramoto
  • ,
  • T Fujita
  • ,
  • N Tezuka
  • ,
  • S Sawai
  • ,
  • H Watanabe
  • ,
  • S Fujino
  • ,
  • T Asai
  • ,
  • Ohkubo, I

317
4
開始ページ
1089
終了ページ
1095
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.bbrc.2004.03.155
出版者・発行元
ACADEMIC PRESS INC ELSEVIER SCIENCE

We have previously reported that 90K/Mac-2 binding protein (M2BP) was highly expressed in lung cancer and that M2BP-specific immunity was observed in many of cancer patients. In this study, we analyzed the ability of 11 M2BP-derived oligopeptides with an HLA-A*0201-binding motif to induce M2BP-specific cytotoxic T lymphocytes (CTL) from peripheral blood lymphocytes of normal donors by in vitro stimulation. One of the CTLs that were induced using M2BP(216-224) (RIDITLSSV) produced interferon-gamma in response to HLA-A2-positive T2 cells pulsed with the same peptide and lysed MDA-MB-231 cells expressing both M2BP and HLA-A2. The cytolytic activities were blocked by antibodies against HLA class I or CD8. These findings suggest that M2BP(216-224) is naturally processed from the native M2BP in cancer cells and recognized by M2BP-specific CTLs in an HLA-A2 restriction. We first identified M2BP-derived CTL epitopes that may be useful as a target antigenic epitope in clinical immunotherapy of cancer. (C) 2004 Elsevier Inc. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.bbrc.2004.03.155
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/15094380
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000221174900018&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.bbrc.2004.03.155
  • ISSN : 0006-291X
  • PubMed ID : 15094380
  • Web of Science ID : WOS:000221174900018

エクスポート
BibTeX RIS